Study to speed up DIPG and DMG research
Part of Brain & nervous system, Cancer clinical trials.
This trial collects information from people with a rare type of brain tumor called DIPG or DMG. The goal is to help researchers learn more about these tumors and find better treatments faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of diffuse midline glioma, including DIPG, or a tumor in certain brain areas like the pons, thalamus, or brainstem.
- You can be at any stage of illness or health status.
- You or your legal representative must agree to join and sign an electronic consent form.
- You also need to join a larger research registry called XCELSIOR.
- You must live in or get treatment in the United States or US territories.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
This trial builds an international registry (a secure collection of patient records) for people who have been diagnosed with DIPG/DMG, including children and adults. Sharing information can help researchers better understand these tumors and plan future studies.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This phase 3 study tests targeted treatments (ONC201 or everolimus) for children with DIPG or similar diffuse midline brain tumors, based on the tumor’s genetic markers. It aims to improve outcomes by matching treatment to the tumor biology and comparing approaches in a randomized way.
Hear when a new Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.